Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits  by Fung, Michael et al.
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 1 113
Objectives: Patients undergoing cardiopulmonary bypass frequently manifest gen-
eralized systemic inflammation and occasionally manifest serious multiorgan fail-
ure. Inflammatory responses of bypass are triggered by contact of blood with arti-
ficial surfaces of the bypass circuits, surgical trauma, and ischemia-reperfusion
injury. We studied the effects of specific inhibition of the alternative complement
cascade by using an anti-factor D monoclonal antibody (166-32) in extracorporeal
circulation of human whole blood used as a simulated model of cardiopulmonary
bypass.
Methods: Five healthy blood donors were used in the study. Monoclonal antibody
166-32 was added to freshly collected, heparinized human blood recirculated in a
pediatric cardiopulmonary bypass circuit at a final concentration of 18 µg/mL. An
irrelevant monoclonal antibody was used as a negative control with the same donor
blood in a parallel bypass circuit on the same day. Blood samples were collected at
different time points during recirculation for measurement of activation of comple-
ment, neutrophils, and platelets by immunofluorocytometric methods and enzyme-
linked immunosorbent assays.
Results: Monoclonal antibody 166-32 inhibited the alternative complement activa-
tion and the production of Bb, C3a, sC5b-9, and C5a. Upregulation of CD11b on
neutrophils and CD62P on platelets was also significantly inhibited by monoclonal
antibody 166-32. This is consistent with the inhibition of the release of neutrophil-
specific myeloperoxidase and elastase and platelet thrombospondin. The production
of proinflammatory cytokine interleukin 8 was also suppressed by the antibody.
Conclusions: The alternative complement cascade is predominantly activated dur-
ing extracorporeal circulation. Anti-factor D monoclonal antibody 166-32 is effec-
tive in inhibiting the activation of complement, neutrophils, and platelets. Inhibition
of the alternative complement pathway by targeting factor D could be useful in
reducing systemic inflammation in patients undergoing cardiopulmonary bypass.
Patients undergoing cardiopulmonary bypass (CPB) frequently mani-fest a generalized systemic inflammatory response syndrome, whichmay contribute to perioperative tissue injury and impaired hemosta-sis.1-6 Serious inflammatory conditions could lead to delayed recov-ery and occasionally to multiorgan dysfunction.1,2,7 Complement acti-vation has been implicated as the most important cause of the
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systemic inflammatory reaction.1,3,4,6,8,9 It is attributed to
the interaction between blood and the artificial surfaces of
extracorporeal circuits constituting CPB machines.10,11
Primary inflammatory substances are generated after activa-
tion of the complement system, including the anaphylatox-
ins C3a and C5a, the opsonin C3b, and the membrane attack
complex C5b-9.12 C3a and C5a are potent stimulators of
neutrophils, monocytes, and platelets.13-16 Activation of
these cells results in release of proinflammatory cytokines
(eg, interleukin 1 [IL-1], IL-6, IL-8, and tumor necrosis fac-
tor α), oxidative free radicals, and proteases.17-22 C5a has
been shown to upregulate adhesion molecules CD11b (α-
integrin) and CD18 (β2-integrin) of Mac-1 in polymor-
phonuclear cells (PMNs; comprising mainly neutrophils)
and to induce degranulation of PMNs to release proinflam-
matory enzymes.15,16,23-27 C5b-9 induces the expression of
adhesion molecule P-selectin (CD62P) on platelets,28
whereas both C5a and C5b-9 induce surface expression of
P-selectin on endothelial cells.29 These adhesion molecules
are involved in the interaction among leukocytes, platelets,
and endothelial cells. The expression of adhesion molecules
on activated endothelial cells is responsible for sequestra-
tion of activated leukocytes, which then mediate tissue
inflammation and injury.24,29,30 In addition, C3a and C5a
stimulate chemotaxis of human mast cells and trigger the
release of histamine, proteases, and leukotrienes, which
induce vascular permeability, vasoconstriction, and tissue
inflammation.31,32
Factor D is the rate-limiting enzyme important for the
activation and amplification of the alternative complement
pathway.33,34 Inasmuch as the concentration of factor D in
human blood is among the lowest of all soluble complement
components (approximately 2 µg/mL),33 factor D is a
potential target for inhibiting the activation of the alternative
complement cascade associated with inflammatory respons-
es. Previously, specific inhibition of the alternative comple-
ment pathway was demonstrated with monoclonal antibod-
ies (MAbs) to human factor D with moderate activity in
complement-mediated hemolytic assays.35 Polyclonal rab-
Figure 1. Selective inhibition of the alternative complement activ-
ity in human whole blood by MAb 166-32 at 18 µg/mL in the extra-
corporeal circulation studies before recirculation. MAb 166-32 did
not inhibit the classical complement activity of the human plasma
in the circuits. The negative control MAb G3-519 had no effects on
either the alternative or the classical complement activity. Values
are given as means ± SD from 5 paired experiments of the test and
control circuits. Percentage of hemolysis was defined as indicat-
ed in the text. P values were determined by means of paired t
tests between MAb 166-32– and MAb G3-519–treated circuits in
the alternative complement hemolytic assays.
Figure 2. Bb and C4d production in the extracorporeal circuits
treated with MAb 166-32 or the negative control MAb G3-519. Bb
(A) and C4d (B) were measured by using a quantitative ELISA.
Values are given as means ± SD from 5 paired experiments of the
test and control circuits. MAb 166-32 completely inhibited the pro-
duction of Bb, indicating complete suppression of the alternative
complement pathway. P values were determined by 2-factor
analysis of variance. There is no significant difference in the
plasma levels of C4d between the test and control circuits as ana-
lyzed with 2-factor analysis of variance.
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bit antibodies to mouse factor D were shown to inhibit alter-
native complement activity in mice.36 We have generated a
potent and specific MAb to human factor D, designated
166-32. The antibody inhibits human factor D at a molar
ratio of about 1:2 in complement-mediated hemolytic
assays.37 The antibody was shown to protect isolated rabbit
hearts from human complement-mediated injury, as mani-
fested by an overall maintenance of myocardial function
after challenge with human plasma.37
Recirculation of human whole blood in extracorporeal
bypass circuits has been used extensively as a simulated
model to study the activation of complement, leukocytes,
and platelets in CPB.15,16,28 The results of our extracorpore-
al circulation studies demonstrate that complete inhibition
of the alternative complement cascade by anti-factor D
MAb 166-32 suppresses activation of neutrophils and
platelets, as well as inhibition of proinflammatory cytokine
IL-8 production.
Methods
Design and Preparation of Extracorporeal Circuits
In the study whole blood was obtained from 5 healthy volunteers
after approval by the Human Investigation Committee of Baylor
College of Medicine. Informed consent was obtained from each
participant. Whole blood from the same donor was used in both
test and negative control circuits on the same day to avoid any vari-
ations in complement activity in donor blood.
Extracorporeal circuits were assembled by using a hollow-fiber
pediatric membrane oxygenator with an integrated heat exchanger
module (D 901 LILLPUT 1; DIDECO, Mirandola, Italy), a pedi-
atric venous reservoir with an integrated cardiotomy filter (D 752
Venomidicard; DIDECO), a perfusion tubing set (Sorin
Biomedical, Inc, Irvine, Calif), and a multiflow roller pump
(Stöckert Instruments GmbH, Munich, Germany). Oxygenator and
circuitry were primed with lactated Ringer’s solution (Baxter
Healthcare Corp, Deerfield, Ill). The prime fluid was warmed to
32°C with a cooler-heater (Sarns/3M Health Care, Ann Arbor,
Mich) and circulated at 500 mL/min, and the sweep gas flow was
maintained at 0.25 L/min with 100% oxygen. The sweep gas was
changed to a mixture of oxygen (95%) and carbon dioxide (5%)
after the blood was added to the circuit. The pH, PCO2, PO2, and
perfusate temperature were continuously monitored throughout the
recirculation period. Sodium bicarbonate was added as required to
maintain pH in the range of 7.25 to 7.40.
Extracorporeal Circuit Operation and Blood Sampling
Blood (250 mL) was drawn over the course of 5 to 10 minutes into
a transfer pack (Haemo-Pak; Chartermed, Inc, Lakewood, NJ)
from healthy volunteers taking no medications. Before blood col-
lection, porcine heparin (Elkins-Sinn, Cherry Hill, NJ) and anti-
factor D MAb 166-32 (mouse immunoglobulin G1) were added to
a transfer pack at final blood concentrations of 5 U/mL and 18
µg/mL, respectively. This concentration of the antibody is equiva-
lent to about 1.5 times the molar concentration of factor D in the
blood. For the negative control, an isotype-matched irrelevant
Figure 3. C3a, sC5b-9, and C5a production in the extracorporeal
circuits treated with MAb 166-32 or the negative control MAb G3-
519. C3a (A), sC5b-9 (B), and C5a (C) were measured by means of a
quantitative ELISA. MAb 166-32 inhibited the production of C3a,
sC5b-9, and C5a in the extracorporeal circuits compared with that
in the MAb G3-519 circuits. Values are given as means ± SD from
5 paired experiments of the test and control circuits. P values
were determined by 2-factor analysis of variance.
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MAb (G3-519) was used at the same final concentration. MAb G3-
519 (mouse immunoglobulin G1) is specific to HIV-1 external
envelope protein gp120. MAb G3-519 has previously been shown
to have no effects on human complement activity.37 The collected
blood was then added to the reservoir through the prime port.
Prime fluid was simultaneously withdrawn distal to the oxygena-
tor outlet to yield a final circuit volume of 350 mL and a final
hematocrit level of 25% to 28%. The pump flow rate was main-
tained at 500 mL/min, and the line pressure of the circuits was
maintained at about 50 mm Hg throughout the entire experiment.
Blood was recirculated with prime fluid, and complete mixing was
accomplished within 3 minutes; a baseline sample was drawn and
designated as time 0. In order to mimic the usual procedures of sur-
gical operation under hypothermia, the circuit was then cooled to
27°C for 70 minutes, after which it was rewarmed to 37°C at 80
minutes. The temperature was maintained until 120 minutes, when
the recirculation was terminated.
Blood samples were collected at 5, 10, 25, 40, 55, 70, 80, and
120 minutes during the recirculation. Plasma samples were pre-
pared by immediate centrifugation at 2000g at 4°C. Aliquots of
plasma were snap-frozen on dry ice and then stored at –80°C. The
plasma samples were used for complement-mediated hemolytic
assays and quantitation of neutrophil-specific myeloperoxidase
and elastase, platelet thrombospondin, C5a, and IL-8. Aliquots of
plasma for measurement of complement products C3a, C4d, sC5b-
9, and Bb by means of enzyme-linked immunosorbent assay
(ELISA) were immediately mixed with an equal volume of a spec-
imen-stabilizing medium (Quidel, San Diego, Calif), snap-frozen
on dry ice, and then stored at –80°C. Samples of whole blood were
also collected for immunostaining of the activation cell-surface
markers CD11b and CD62P on neutrophils and platelets, respec-
tively. To prevent subsequent complement activation of the whole
blood samples during the staining procedure, we added 10 µL of 1
mol/L ethylenediamine tetra-acetic acid to every milliliter of
whole blood to give a final concentration of 10 mmol/L.
Complement-Mediated Hemolytic Assays
The alternative complement activity in the plasma samples from
MAb 166-32–treated and MAb G3-519–treated circuits was mea-
sured with the use of rabbit red blood cells (RBCs). The plasma
samples were treated with ethylene glycol-bis-(β-aminoethyl
ether)-N,N,N´,N´-tetra-acetic acid (EGTA) at a final concentration
of 50 mmol/L to chelate Ca++ for inhibition of the classical com-
plement. Thirty microliters of rabbit RBC suspension (1.7 × 108
cells/mL) in gelatin/veronal-buffered saline solution (GVB/Mg-
EGTA) containing 2 mmol/L MgCl2 and 50 mmol/L EGTA were
added to 100 µL of human plasma (final plasma concentration,
Figure 5. Inhibition of myeloperoxidase (MPO) and elastase
release from neutrophils in the extracorporeal circuits treated
with MAb 166-32 compared with that in the circuits treated with
the negative control MAb G3-519. Myeloperoxidase (A) and elas-
tase-α1-antitrypsin inhibitor complex (B) were measured by a
quantitative ELISA. Elastase released from activated neutrophils
is quickly bound to α1-antitrypsin inhibitor in the blood. Values
are given as means ± SD from 5 paired experiments of the test and
control circuits. P values were determined by 2-factor analysis of
variance.
Figure 4. Inhibition of CD11b expression on PMNs in the extracor-
poreal circuits treated with MAb 166-32 compared with the cir-
cuits treated with the negative control MAb G3-519. The expres-
sion level of CD11b was measured by means of an
immunofluorocytometric method and is expressed as the percent-
age of mean channel fluorescence intensity relative to the value
at time 0 (100%). Values are given as means ± SD from 5 paired
experiments of the test and control circuits. P values were deter-
mined by 2-factor analysis of variance.
B
A
Fung et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 1 117
TX
ET
CS
P
CP
S
CH
D
G
TS
ED
IT
O
RI
A
L
77%). After incubation at 37°C for 30 minutes, the supernatants
were collected, and optical density (OD) was read at 405 nm by
using an ELISA plate reader. This OD reading was designated as
ODA. One hundred microliters of each plasma sample was mixed
with 30 µL of GVB/Mg-EGTA to give the plasma color back-
ground (ODB). For 100% hemolysis, 100 µL of water was mixed
with 30 µL of rabbit RBC suspension. This OD reading was des-
ignated as OD100. The percentage of hemolysis was determined by
the following formula:
Percentage hemolysis = 100 × (ODA – ODB)/OD100
Spontaneous lysis of RBCs was negligible.
For classical pathway hemolysis, chicken RBCs (5 × 107
cells/mL) in GVB++ containing 0.5 mmol/L MgCl2 and 0.15
mmol/L CaCl2 were sensitized with purified antichicken RBC
immunoglobulins at 8 µg/mL (InterCell Technologies, Hopewell,
NJ) for 15 minutes at 4°C. The cells were then washed with
GVB++. The plasma samples were not treated with EGTA. The
remaining procedures were identical to those for alternative path-
way hemolysis described above.
Assays of Complement Activation Products
Plasma samples from the extracorporeal circuits were tested for the
levels of Bb, C4d, C3a, and sC5b-9. Bb is a specific marker for the
activation of the alternative complement pathway, whereas C4d is
for the classical complement pathway. These substances were mea-
sured by means of commercially available quantitative ELISA kits
(Quidel) according to the manufacturer’s manuals.
Assays for Expression of CD11b on Neutrophils and
CD62P on Platelets
The activation of neutrophils and platelets was quantitated by mea-
suring the levels of the cell-surface expression of CD11b and CD62P
on neutrophils and platelets, respectively. For CD11b labeling of neu-
trophils, 100 µL of whole blood collected from the circuits was
immediately incubated with 20 µL of phycoerythrin-anti-CD11b
antibody (Becton Dickinson, San Jose, Calif) for 10 minutes at room
temperature. Then 1.4 mL of FACS Lysing solution (Becton
Dickinson) was added for 10 minutes at room temperature to lyse
RBCs and to fix leukocytes. The cells were then washed in phos-
phate-buffered saline solution and then fixed in 1% paraformalde-
hyde before analysis with an EPIC-XL flow cytometer (Coulter Corp,
Miami, Fla). For double labeling to concomitantly identify the neu-
trophil population, fluorescein isothiocyanate (FITC)-anti-CD15
antibody (Becton Dickinson) was added for incubation together with
phycoerythrin-anti-CD11b antibody.
For CD62P labeling of platelets, 40 µL of whole blood collect-
ed from the circuits was incubated with 20 µL of phycoerythrin-
anti-CD62P antibody (Becton Dickinson) for 10 minutes at room
temperature. Then the mixture was treated with FACS Lysing solu-
tion as described above. The platelets were washed in phosphate-
buffered saline solution, fixed in 1% paraformaldehyde, and then
analyzed as described above. For double labeling to concomitant-
ly identify the platelet population, FITC-anti-CD41 antibody
(Coulter) was added for incubation together with phycoerythrin-
anti-CD62P antibody.
For flow cytometric measurement, PMN and platelet popula-
tions were identified by live gating on the basis of forward-scatter
versus side-scatter parameters and specific staining with FITC-
anti-CD15 antibody and FITC-anti-CD41 antibody, respectively.
The background staining was gated by means of isotype-matched
labeled antibodies. The intensity of expression of CD11b and
CD62P was represented by the mean fluorescence intensity.
Assay of C5a
C5a was measured quantitatively with an ELISA. Plasma samples
were first treated with a precipitating reagent from a C5a radioim-
munoassay kit (Amersham, Arlington Heights, Ill) to remove high-
molecular-weight proteins, including C5. In the C5a ELISA puri-
fied rabbit anti-C5a antibodies (Calbiochem, La Jolla, Calif) were
coated on wells of microtest plates to immobilize C5a in plasma
samples. Purified sheep anti-human C5 antibodies (Biodesign,
Kennebunk, Maine) were used to capture the immobilized C5a.
The bound sheep antibodies were then detected by using horserad-
ish peroxidase rabbit anti-sheep immunoglobulin G (Fc) antibod-
ies (Jackson ImmunoResearch, West Grove, Pa). Peroxidase sub-
Figure 6. Inhibition of CD62P expression on platelets in the extra-
corporeal circuits treated with MAb 166-32 compared with the
circuits treated with the negative control MAb G3-519. The per-
centages of CD62P+ platelets (A) and the CD62P expression level
in mean fluorescence intensity on platelets (B) are represented
relative to the values at time 0 (100%). Values are given as means
± SD from 5 paired experiments of the test and control circuits. P
values were determined by 2-factor analysis of variance.
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strate solution was added for color development, and OD450 was
measured by means of an ELISA plate reader. Purified C5a
(Advanced Research Technologies, San Diego, Calif) was used as
the standard for calibration.
Assay of Neutrophil-Specific Myeloperoxidase
Activation of neutrophils was also measured with an ELISA kit
(R&D Systems, Inc, Minneapolis, Minn) to quantitate the amount
of neutrophil-specific myeloperoxidase in the plasma samples
from the extracorporeal circuits. The assays were performed
according to the manufacturer’s manual.
Assay of Elastase-α1-Antitrypsin Inhibitor Complex
A quantitative ELISA was used to measure neutrophil-specific
elastase-α1-antitrypsin inhibitor complex, as described previous-
ly.16 On activation, neutrophils release elastase, which is immedi-
ately complexed with α1-antitrypsin inhibitor in the blood.16 The
assay used sheep anti-human neutrophil elastase polyclonal anti-
bodies (Biodesign) to immobilize the complex and horseradish
peroxidase–conjugated sheep anti-α1-antitrypsin inhibitor poly-
clonal antibodies (Biodesign) for detection. As a calibration stan-
dard, elastase-α1-antitrypsin inhibitor complex was made by mix-
ing neutrophil-specific elastase (Elastin Products Company, Inc,
Owensville, Mo) with α1-antitrypsin inhibitor (Calbiochem).
Assay of Platelet Thrombospondin
A quantitative ELISA was used to measure platelet throm-
bospondin, which is an α-granule glycoprotein involved in platelet
aggregation and is released on activation. In the assay throm-
bospondin was captured by using a pair of noncompetitive
antithrombospondin MAbs, as described previously.38 Monoclonal
antithrombospondin antibody (clone P12, Coulter) was coated on
wells of microtest plates to immobilize plasma thrombospondin.
Biotinylated monoclonal antithrombospondin antibody (clone P10,
Coulter) was used to capture immobilized thrombospondin.
Purified thrombospondin (Calbiochem) was used as a calibration
standard in the assay.
IL-8 ELISA
IL-8 was measured by using a quantitative ELISA kit (R&D
Systems).
Statistical Analysis
The data from 5 paired circuits were statistically analyzed and rep-
resented as means ± SD. The data of hemolytic assays were ana-
lyzed with paired t tests. A 2-factor analysis of variance in a ran-
domized block design was used to analyze the data from the other
assays.
Results
Selective Inhibition of the Alternative Complement
Activity by MAb 166-32
In the extracorporeal circulation study, MAb 166-32 was
added to heparinized human whole blood at a final molar
concentration of 1.5 times that of factor D in the blood. An
isotype-matched negative control MAb, G3-519, was also
studied at the same concentration in a parallel circuit by
using whole blood from the same donor on the same day.
The alternative and classical complement activities in the
blood treated with the antibodies before recirculation were
measured by means of hemolytic assays with rabbit RBCs
and sensitized chicken RBCs, respectively. In the alternative
pathway hemolytic assays, plasma from MAb G3-
519–treated circuits at a final concentration of 77% induced
lysis of rabbit RBCs by 65%, whereas no hemolysis was
observed with plasma from MAb 166-32–treated circuits
(Figure 1). In contrast, neither MAb 166-32 nor MAb G3-
519 inhibited the lysis of sensitized chicken RBCs through
the classical complement pathway (Figure 1). Therefore,
MAb 166-32 is a selective and potent inhibitor of the alter-
native complement pathway.
Complement Activation in Extracorporeal Circuits
The selective inhibition of the alternative complement path-
way by MAb 166-32 is in agreement with the complete inhi-
bition of the production of Bb throughout the entire duration
of recirculation (Figure 2, A). Bb is the enzymatic product
of factor B on proteolysis by factor D, and therefore it is a
specific marker for the activation of the alternative comple-
ment pathway. On the other hand, there was an increase in
the plasma concentration of C4d in both circuits treated with
either MAb 166-32 or MAb G3-519 (Figure 2, B). C4d is a
specific marker for activation of the classical complement
pathway.
The plasma concentrations of C3a, sC5b-9, and C5a in
the extracorporeal circuits during recirculation were also
measured. MAb 166-32 strongly inhibited the production of
these substances (Figure 3, A-C). The formation of sC5b-9
Figure 7. Inhibition of thrombospondin release from platelets in
the extracorporeal circuits treated with MAb 166-32 compared
with that in the circuits treated with the negative control MAb G3-
519. Thrombospondin was measured by means of a quantitative
ELISA. Values are given as means ± SD from 5 paired experiments
of the test and control circuits. P values were determined by 2-
factor analysis of variance.
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and C5a was completely inhibited during recirculation at
hypothermic temperatures. At the end of 120 minutes of
recirculation, MAb 166-32 inhibited the production of C3a,
sC5b-9, and C5a by 67%, 77%, and 88%, respectively, com-
pared with that of the negative control MAb G3-519.
Because the alternative complement activity of the plasma
in the test circuits was completely inhibited by MAb 166-
32, the production of C3a, sC5b-9, and C5a in these circuits
could be attributed to some activation of the classical path-
way, as indicated by the elevation of plasma C4d levels
(Figure 2, B).
Activation of Neutrophils in Extracorporeal Circuits
Activation of neutrophils as manifested by upregulation
of surface expression of CD11b was measured by means
of immunocytofluorometric analyses. The expression of
CD11b on neutrophils in circuits treated with MAb 166-32
was significantly reduced compared with the negative con-
trol MAb G3-519 (Figure 4). At the end of 120 minutes of
recirculation, MAb 166-32 inhibited CD11b expression on
neutrophils by 57% compared with MAb G3-519.
The activation of neutrophils was also studied by measur-
ing the levels of neutrophil-specific myeloperoxidase and elas-
tase in plasma. The enzymes are stored in azurophilic primary
granules of neutrophils and released on degranulation of acti-
vated neutrophils.25-27 Consistent with the inhibition of neu-
trophil activation as manifested by the upregulation of CD11b
expression (Figure 4), the release of both myeloperoxidase
and elastase was also significantly inhibited by MAb 166-32
in the extracorporeal circuits compared with in the MAb G3-
519–treated circuits (Figure 5, A and B). At the end of 120
minutes of recirculation, MAb 166-32 inhibited the release of
myeloperoxidase and elastase by 67% and 41%, respectively,
compared with MAb G3-519.
Activation of Platelets in Extracorporeal Circuits
The effects of MAb 166-32 on platelet activation during
recirculation in extracorporeal circuits were examined. The
number of CD62P+ platelets and the level of CD62P expres-
sion were significantly reduced in MAb 166-32–treated cir-
cuits compared with in MAb G3-519–treated circuits
(Figure 6, A and B). At the end of 120 minutes of recircula-
tion, the number of CD62+ platelets and the level of CD62
expression were reduced by 45% and 54%, respectively, in
MAb 166-32–treated circuits compared with in MAb G3-
519–treated circuits. These results corroborate with the inhi-
bition of thrombospondin release from activated platelets by
MAb 166-32 treatment by 53% at the end of 120 minutes of
recirculation compared with MAb G3-519 (Figure 7).
Production of IL-8 in Extracorporeal Circuits
To further examine the effects of complement inhibition on
other inflammatory responses in whole blood during recir-
culation, we examined the production of the proinflamma-
tory cytokine IL-8 in the test and control extracorporeal cir-
cuits. IL-8 is produced predominantly by activated neu-
trophils, monocytes-macrophages, and T cells. During the
recirculation at hypothermic temperatures, the plasma levels
of IL-8 did not increase, even in MAb G3-519–treated cir-
cuits. However, the plasma levels of IL-8 increased dramat-
ically when the circuits were warmed to 37°C. At the end of
120 minutes of recirculation, IL-8 production in MAb 166-
32–treated circuits was significantly reduced by 73% com-
pared with MAb G3-519–treated circuits (Figure 8).
Discussion
The complement cascade is activated predominantly
through the alternative or the classical pathway.12 Activation
of the alternative complement pathway is induced through
the direct activation of C3, whereas the classical comple-
ment pathway is activated through the initial activation of
C1. Recent studies show that complement can also be acti-
vated through the lectin pathway, which involves the initial
binding of mannose-binding lectin and the subsequent acti-
vation of C2 and C4, which are common to the classical
complement pathway.39,40 Interestingly, accumulating evi-
dence indicates that the alternative complement pathway
participates in the amplification of the activity of both the
classical complement and the lectin pathways as a result of
C3b deposition, which triggers the formation of the alterna-
tive C3/C5 convertases.40,41 Therefore, the alternative com-
plement pathway may play a broad role in inflammation
resulting from complement activation.
In CPB circuits the alternative complement pathway
plays a predominant role in complement activation, result-
Figure 8. Inhibition of IL-8 production in the extracorporeal cir-
cuits treated with MAb 166-32 compared with that in the circuits
treated with the negative control MAb G3-519. IL-8 was measured
by a quantitative ELISA. Values are given as means ± SD from 5
paired experiments of the test and control circuits. P values were
determined by 2-factor analysis of variance.
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ing from the interaction of blood with the artificial surfaces
of CPB circuits.1,6,11 However, natural human antibodies
against dialysis membranes have been described, and it is
possible that natural antibodies against components of the
CPB circuits or membrane could be responsible for the C4d
production in our study.42 Interestingly, the alternative com-
plement pathway was shown to play a crucial role in the
amplification of the classical complement pathway once it
was initiated.42 In addition, activation of the classical com-
plement pathway in CPB circuits could also be triggered by
means of contact activation of the intrinsic coagulation path-
way.10,43,44 As a result, factor XIIa, factor XIa, and
kallikrein bind C1 esterase inhibitor, an endogenous
inhibitor of activated C1. When the plasma concentration of
C1 esterase inhibitor is diminished, C1 becomes more sus-
ceptible to activation, and thus the classical complement
pathway is augmented. Inasmuch as the production of C5a
and sC5b-9 was substantially inhibited compared with that
of C3a in our study, the moderate activation of the classical
pathway as indicated by the formation of C4d during
hypothermic recirculation does not seem to effectively acti-
vate C5. Similarly, although protamine neutralization of
heparin after CPB causes activation of the classical comple-
ment pathway,6,45 the activation of C5 by protamine-heparin
complexes is found to be ineffective.6,8 Using anti-factor D
MAb 166-32 to selectively inhibit the alternative comple-
ment pathway, we confirm the previous findings that the
alternative complement pathway is predominantly activated
in CPB circuits.1,6,8
The results from our study show that anti-factor D MAb
166-32 is a potent and specific inhibitor of the alternative
complement pathway. At a concentration (18 µg/mL) equiv-
alent to 1.5 times the molar concentration of factor D in
human blood, MAb 166-32 completely inhibits the alterna-
tive complement activity, as evidenced by the complete
blockade of Bb formation in the CPB circuits. Inhibition of
the alternative complement pathway by anti-factor D MAb
166-32 suppresses the production of C3a, sC5b-9, and C5a.
These substances are known to activate neutrophils, mono-
cytes, platelets, mast cells, and endothelial cells.13-16,28,29
Reduction of CD11 (α-integrin) expression on neutrophils
prevents their binding to platelets and endothelial cells
through the interaction with CD62P on these cells.46,47
Sequestration of activated neutrophils on endothelial cells
can result in tissue inflammation and injury.24,29,30 It has
been shown that CD11b expression on monocytes is
increased by C3a but not C5a and sC5b-9 in CPB cir-
cuits.15,16 Therefore, the reduction of C3a production by
MAb 166-32 in our study could be important for controlling
monocyte adhesion. Although the exact roles of activated
monocytes in the inflammatory response of CPB have yet to
be delineated, it is likely that proinflammatory cytokine
release and tissue factor–mediated thrombosis are
involved.13,48 Because CR3 (Mac-1; CD11/CD18) on
leukocytes can bind to iC3b on complement-activated sur-
faces in CPB circuits,49 this could contribute to the deple-
tion of leukocytes commonly observed in patients undergo-
ing CPB.15,44 Inhibition of CD11b upregulation by MAb
166-32 in our study could prevent the loss of leukocytes
during extracorporeal circulation.
The results from our study also show that inhibition of
the alternative complement pathway by anti-factor D MAb
166-32 suppresses the degranulation of neutrophils, as indi-
cated by the reduced release of myelopoxidase and elastase.
Myeloperoxidase is responsible for production of
hypochlorous acid, a potent oxidant that could cause tissue
damage, whereas elastase could mediate tissue injury as a
result of hydrolysis of elastin in extracellular matrices.25-27
The incomplete inhibition of neutrophil degranulation by
anti-factor D MAb 166-32 in this study might be attributed
to contact activation, which results in the production of
kallikrein, a mediator that is known to activate neutrophils
to release elastase.50 Similarly, platelets could be activated
by thrombin as a result of initiation of the intrinsic coagula-
tion pathway after contact activation.51
IL-8 is closely associated with inflammatory diseases
and CPB.19-22 Our results show that anti-factor D MAb
reduces the release of IL-8. IL-8 causes chemotaxis of neu-
trophils, T cells, and basophils; degranulation of neu-
trophils; and adhesion of neutrophils to endothelial cells.30
Therefore, the reduction of IL-8 production could reduce
multiple inflammatory responses observed in CPB. Delayed
increase of plasma IL-8 in our extracorporeal circulation
study is consistent with the observation in operations
involving CPB.19,21,22
One limitation of the simulated extracorporeal circula-
tion model of CPB used in this study is the inability to study
the inflammatory responses of endothelial cells caused by
complement activation. In this regard, both C5a and C5b-9
were shown to induce surface expression of P-selectin on
endothelial cells.29
Several complement inhibitors are being studied for
potential applications in CPB. They include a recombinant
soluble complement receptor 1 (sCR1),52 a humanized sin-
gle-chain anti-C5 antibody (h5G1.1-scFv),53 a recombinant
fusion hybrid (CAB-2) of human membrane cofactor pro-
tein and human decay accelerating factor,16 and a 13-residue
C3-binding cyclic peptide (Compstatin).54 sCR1 and CAB-
2 inhibit the classical and alternative complement pathways
at the steps of C3 and C5 activation. Compstatin inhibits
both complement pathways at the step of C3 activation,
whereas h5G1.1-scFv does so only at the step of C5 activa-
tion. The results of our study strongly indicate that the alter-
native complement activation plays an important role in
inducing a plethora of cellular and humoral inflammatory
responses in CPB. Anti-factor D MAb 166-32 is effective in
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inhibiting the activation of C3 and C5 and the other inflam-
matory responses in extracorporeal circulation. Therefore,
complete inhibition of the alternative complement pathway
by targeting factor D could be useful to reduce systemic
inflammation in patients undergoing CPB.
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